Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024
"Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust developmen ...
Interesting Engineering on MSN4h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
Monthly Prescribing Reference9h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
FDA approves tablet form of Evrysdi for spinal muscular atrophy
The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea
Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a ...
Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA
Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP)NEW YORK, Feb. 18, 2025 ...
Medivir AB: Year-End Report January - December 2024
"We are now, within short, ready to initiate the phase 2b study - with the goal of making fostrox + Lenvima the first approved medical treatment for second-line liver cancer" October - DecemberFinanci ...